Table 3 Arrhythmic effects of sotalol, quinidine, and E-4031 observed during the field potential (FP) recordings
Sotalol (µM) | hESC (n = 11) | WTa (n = 6) | WTb (n = 12) | LQT1A (n = 13)*,s | LQT1B (n = 13)*,a | LQT2 (n = 15)a |
|---|---|---|---|---|---|---|
0.8 | ||||||
1.6 | ||||||
5.7 | AD(2) | |||||
9.7 | AD(4) | AD(1) | ||||
19.4 | AD(1) | AD(2) |
Quinidine (µM) | hESC (n = 10) | WTa (n = 6) | WTb (n = 11) | LQT1A (n = 12)*,s | LQT1B (n = 16)*,a | LQT2 (n = 12)a |
|---|---|---|---|---|---|---|
1.5 | ||||||
3 | AD(1) | |||||
9 | AD(3) | BA(7) | AD(1) | BA(5) | BA(5) | |
15 | BA(2) | BA(2) | ||||
30 | BA(1) |
E-4031 (nM) | hESC (n = 10) | WTa (n = 6) | WTb (n = 8) | LQT1A (n = 16)*,s | LQT1B (n = 16)*,a | LQT2 (n = 13)a |
|---|---|---|---|---|---|---|
10 | ||||||
100 | BA(4) | |||||
300 | AD(7) | AD(2) | AD(8) | AD(3) | ||
500 | BA(1) | BA(2) | BA(1) | AD(4) | ||
700 | BA(1) |